Vertex Raises Revenue, Not Earnings, and Buys a Fifth Pillar That Does Not Pay Until 2029

Results vs. Consensus

Q2 2026 Scorecard

A note on the EPS line, because it is the one figure where the vendors disagree and where the disagreement matters. Published consensus for non-GAAP EPS ranged from $4.72 to $4.75 across three independent captures. The $4.73 actual sits inside that range. Calling it a beat or a miss would be an artefact of which vendor one happened to open, so we call it in line and move on. What is not ambiguous is the shape: a 3.2% revenue beat converted into no earnings surprise at all.

Year-over-year comparison

Two mechanical points before the interpretation. Total revenue grew 12.5% while product revenue grew 13.2%, and the difference is not a slowdown: the prior-year quarter carried $20.7M of collaboration revenue that has now gone to zero. Management flagged this on the call. Second, GAAP EPS grew faster than non-GAAP EPS this quarter (+8.0% against +4.7%), the opposite of the usual pattern, because a $37.2M favourable swing in the fair value of strategic investments flows into the GAAP line and is stripped out of the non-GAAP line. Anyone anchoring on the GAAP growth rate is measuring a mark-to-market gain on a venture portfolio.

Sequential comparison

Vertex reports three-month and six-month columns, so the Q1 2026 standalone figures below are the arithmetic difference between them. That derivation validates on three independent anchors: it reproduces Q1 total revenue of $2,986.9M, Q1 combined non-GAAP operating expense of $1,292.0M, and Q1 non-CF revenue of $71.9M, all three of which match what was reported in April.

Revenue. This was the strongest top-line print Vertex has delivered in six quarters, and it was not narrow. The CF franchise grew 10.6% year over year against a base that many investors had modelled as a low-single-digit annuity, and it did so while the flagship product declined: TRIKAFTA/KAFTRIO fell 2.1% year over year even as ALYFTREK grew 266%. That combination is the single most important datum in the release, and we return to it below. The non-CF line, which we flagged in April as the weakest part of the story, grew 197.2% year over year and 75.2% sequentially. Against that, the second-half revenue task implied by the raised guide is a step down in growth, not up: the midpoint implies $6,829.2M in the second half, about 9.0% above the year-ago half against the 10.2% the first half delivered. Management pre-explained why, noting that first-half CF growth "was 8%, including the benefit of prior year U.S. price increases and foreign exchange", and that both factors "contribute less to growth in the second half of the year."

Margins. The gross margin trajectory is now doing exactly what the company said it would do in February, which is the problem: it was never going to be a surprise, and it was always going to compress. First-half non-GAAP gross margin was 86.3%. For the full year to land at the reiterated "just under 86%," the second half has to run near 85.5%, below the 85.6% just printed. Management said the mix and manufacturing pressure "will be more pronounced in the second half than they were in the first half of 2026", which is a clear statement that Q2's 85.6% is a ceiling for the back half rather than a floor. The operating margin story is separate and worse: combined non-GAAP operating expense grew 15.4% year over year against 12.5% revenue growth, and the composition is the point. Non-GAAP R&D grew 1.2%; non-GAAP SG&A grew 44.7%. Vertex is not spending more on science, it is spending far more on selling.

EPS. Here is the sentence that should govern how this quarter is read. Revenue grew 12.5%, non-GAAP operating income grew 7.4%, non-GAAP net income grew 3.2%, and non-GAAP EPS grew 4.7% only because 1.4% of the share count was retired. Every step down that ladder is a real cost: 92bps of gross margin, 200bps of operating margin, 170bps of tax rate. The company is converting a very good revenue quarter into an ordinary earnings quarter, and it is doing so deliberately, because the spending buys the fourth and fifth franchises. That is a defensible strategy. It is also, at 25.7x forward earnings, a strategy the market is already paying for in full.

Revenue Performance by Product

Cystic fibrosis: the conversion accelerated, and the flagship's decline narrowed

At initiation we argued the ALYFTREK switch was additive rather than substitutive, on the evidence that the TRIKAFTA-plus-ALYFTREK pair grew 7.3% year over year in Q1. That pair grew 13.4% year over year this quarter. The conversion is not just additive, it accelerated, and it did so in the same quarter TRIKAFTA/KAFTRIO's year-over-year decline narrowed to 2.1%, from 7.1% in Q1. Those two facts together are the cleanest confirmation of the bull case in the release: Vertex is cannibalising its own flagship, which still carries three-quarters of total revenue, and the franchise is growing faster while it happens.

"ALYFTREK performance has been excellent and crossed another significant milestone, exceeding $1 billion in revenue in the first half of 2026. In the U.S., we continue to see patients initiating ALYFTREK who are new to therapy, returning to therapy and patients switching from TRIKAFTA. The majority of ALYFTREK revenue continues to come from these TRIKAFTA switch patients, which reflects the benefits of ALYFTREK and our success establishing ALYFTREK as the new standard of care." — Duncan J. McKechnie, Chief Commercial Officer

The international picture is running ahead of the U.S. Outside the U.S., CF revenue grew 12% year over year against 9% in the U.S., helped by currency and by order timing but also by a genuine regulatory tailwind: ALYFTREK is now reimbursed in 25 countries after four additions in the quarter including Spain, with a letter of intent signed with the Pan-Canadian Pharmaceutical Alliance. Management disclosed that in Germany and the U.K., more than one in three eligible CF patients are now on ALYFTREK, and that the European launches carry no requirement for augmented liver monitoring, which removes a friction the U.S. label still carries.

The honest caveat sits in the company's own numbers. First-half global CF growth was 8%, not the 11% Q2 delivered, and the second quarter was flattered by items that do not repeat.

"Note that global CF revenue growth for the first half of 2026 was 8%, including the benefit of prior year U.S. price increases and foreign exchange. We expect both of these factors to contribute less to growth in the second half of the year." — Charles Wagner, Chief Operating Officer and Chief Financial Officer

Assessment: The pillar is intact and strengthening, but the growth rate an investor should carry forward is the 8% first-half figure with a haircut, not the 11% Q2 figure. The genuinely new information is the label-expansion runway: submissions are in progress for ALYFTREK in children aged 2 to 5 and TRIKAFTA in patients aged 1 to 2, and the ECFS data showed 65% of children aged 2 to 5 reaching carrier-level sweat chloride below 30 mmol/L. Each expansion adds patients at the top of a funnel that then converts to the newer, higher-priced product. That is a two-to-three year runway that does not depend on any pipeline asset working.

CASGEVY: the growth arrived, the disclosure did not

CASGEVY delivered $76.4M, up 78.1% sequentially and 151.3% year over year, comfortably the best quarter the product has had. Management framed it as expected rather than surprising, which is a meaningful claim given how lumpy the revenue has been, and backed it with three commercial proof points: FDA approval in children aged 2 and older achieved 53 days post-filing, which expands eligibility by approximately 5,500 patients; reimbursement secured in Germany; and completed submissions in Saudi Arabia and the U.K. for the 5-to-11 cohort.

"During the second quarter, we delivered $76 million in CASGEVY revenue, reflecting approximately 75% sequential growth versus quarter 1, 2026 and over 150% year-over-year growth. This was in line with our expectations based on our visibility into patient scheduling patterns." — Duncan J. McKechnie, Chief Commercial Officer

What did not arrive is the quarterly infusion count. We flagged its withdrawal in April as the single sharpest disclosure signal in that print, and asked whether it would return. It did not. In its place management offered two constructions, both of which are floors rather than figures.

"There were more CASGEVY infusions in the first half of 2026 than in all of 2025. Second quarter 2026 was also the third sequential quarter with more than 100 patient initiations, which enhances our visibility to continued growth for the rest of this year and early 2027 as patients continue to move through cell collection, editing and infusion." — Duncan J. McKechnie, Chief Commercial Officer

Assessment: The revenue trajectory is now good enough that the disclosure question matters less than it did in April, and we downgrade our concern accordingly. But "more than 100 patient initiations" for the third consecutive quarter is a statement that is equally true at 101 and at 300, and a company genuinely accelerating would have less reason to keep using it. The metric substitution is worth remembering when the next lumpy quarter arrives, because the reason management gives for lumpiness is the same reason it has stopped publishing the number that would let anyone verify it: "Quarter-to-quarter variability in CASGEVY revenue will continue and reflects the timing of patient infusions as people choose to receive their infusions when it best suits them."

JOURNAVX: prescriptions are the signal, revenue is partly noise

JOURNAVX generated $49.6M, up 71.0% sequentially, against prescription growth of roughly 45%. In April management promised that revenue growth would "significantly exceed prescription growth" as gross-to-net improved, and on the arithmetic it did. The prescription base is genuinely strong: approximately 535,000 in the quarter and just over 900,000 in the first half, split roughly evenly between hospital and retail, with monthly prescriptions in each channel doubling from about 50,000 in January to about 100,000 in June. Roughly 18,000 new prescribers were added in the quarter, and JOURNAVX now sits on 1,400 hospital and 130 IDN pathways.

The revenue quality is a different question, and to management's credit they raised it themselves rather than waiting to be asked.

"Unpacking Q2 performance, revenue was positively impacted by channel build after we've seen a drawdown in quarter 1. At this stage in an acute product launch, we continue to expect some quarterly volatility in inventory build and drawdown as full-line wholesalers and retail channel buying patterns normalize to reflect formulary adoption, physician awareness and seasonality in elective surgeries." — Duncan J. McKechnie, Chief Commercial Officer

Implied net revenue per prescription rose to about $93 from about $80 for the first quarter on the same first-half basis, which is progress, but it remains well below the roughly $108 per prescription implied across 2025. And the reason it remains below has now been given a new deadline. Gross-to-net normalisation was framed as "late 2026, early 2027" in February, tightened to "by the end of the year" in May, and has now moved again.

"The consequence of this rapid prescription growth is that we are seeing greater use of the PSP program than we forecast as securing unrestricted payer access and physician education catches up with prescription growth. ... As a result, we continue to expect gross to net to normalize in line with other branded oral medicines, but now in the first half of 2027." — Duncan J. McKechnie, Chief Commercial Officer

Assessment: Treat prescriptions as the demand signal and revenue as a lagging, noisier derivative of it. On that basis the launch is working: 45% sequential prescription growth with broadening prescriber breadth is a real acute-pain franchise forming. The gross-to-net slip is the third consecutive delay to the same milestone, and each delay has come with a reasonable-sounding explanation, which is precisely why the pattern rather than any single explanation is what to weigh. Management's framing, that heavy patient-support-programme usage is a deliberate cost of converting prescribers away from opioids, is strategically coherent. It also means the revenue line understates the franchise today and will overstate its growth rate whenever normalisation eventually lands.

Renal: still no revenue, now with a date

The renal franchise contributed nothing to the quarter and consumed a material and growing share of the SG&A line, which is the same shape as April. What changed is that the launch stopped being hypothetical. The FDA accepted the povetacicept BLA for accelerated approval in IgA nephropathy and set a PDUFA target action date of November 30, 2026. Behind it, the OLYMPUS Phase 2/3 study in primary membranous nephropathy has completed its Phase 2 portion with the independent monitoring committee selecting 80mg subcutaneously every four weeks for Phase 3; the gMG Phase 2 proof-of-concept study is on track to complete enrolment by year-end; AMPLITUDE is on track for full enrolment by year-end with interim results in early 2027; AMPLIFIED has completed enrolment and dosing with results due this autumn; and AGLOW in ADPKD has completed enrolment.

Commercial readiness is further along than we expected at this stage. The renal field force is fully hired, roughly 90% with nephrology experience, and management claims scale advantage against the competitive set.

"We have completed the hiring of our renal field force of whom about 90% have nephrology experience and was built with the breadth of our renal pipeline in mind. We anticipate that we will have the largest field force among the novel APRIL or APRIL + BAFF therapies for IgAN." — Duncan J. McKechnie, Chief Commercial Officer

Assessment: A dated PDUFA four months out is materially better than the undated filing we were underwriting in April, and it is the main reason our valuation band moves up a turn this quarter. The cost side has not improved: non-GAAP SG&A grew 44.7% year over year with management attributing the commercial investment as being "split roughly evenly between pain and renal", which means Vertex is now funding two full commercial build-outs against one of which has never sold a unit. The payoff is real but it is 2027 revenue at the earliest, and the spending is 2026 earnings.

Key Topics & Management Commentary

Overall Management Tone: Confident and, unusually for this company, pre-emptive. Management volunteered three pieces of unflattering detail before anyone asked for them: that JOURNAVX revenue was helped by channel build after a first-quarter drawdown, that gross-to-net normalisation had slipped again, and that combined operating expense would land at the high end of its range. That is a marked change from the April call, where the equivalent disclosures had to be extracted in Q&A. The posture on the pipeline was the most assured of the past four quarters, with the povetacicept PDUFA date and the record-pace CASGEVY paediatric approval delivered as routine updates. The one place management was noticeably less forthcoming was capital allocation, where the largest acquisition in company history was handled in a few prepared sentences that referred back to a separate call held a month earlier and drew no questions at all.

1. The revenue raise is real; the earnings raise is not

Vertex raised full-year revenue guidance to $13.1B-$13.2B from $12.95B-$13.1B, lifting the midpoint $125M, or 1.0%. Against a fiscal 2025 base of $12,001.3M that takes implied full-year growth from about 8.5% to a range of 9.2% to 10.0%. It is a genuine raise driven by a genuine beat, and the first-half performance supports it.

Underneath the revenue line, three separate items moved against earnings, all disclosed on the same call. Combined non-GAAP operating expense guidance was reiterated at $5.65B-$5.75B but steered to the top of it. The non-GAAP effective tax rate printed 21.1% for the quarter, above the top of the 19.5%-20.5% full-year range, leaving the year-to-date figure at 20.4% and very little room. And the gross margin guide of "just under 86%" was left unchanged with the explicit warning that second-half pressure exceeds first-half pressure.

"On operating expenses, we are reiterating our combined non-GAAP operating expense guidance of $5.65 billion to $5.75 billion, though we now expect to be at the high end of that range." — Charles Wagner, Chief Operating Officer and Chief Financial Officer

Netting it out on our own model: a $125M revenue raise at roughly 86% gross margin generates about $107M of incremental gross profit; moving to the high end of the opex range absorbs roughly $50M against the prior midpoint; and a tax rate at the top rather than the middle of its range takes most of the rest. Our full-year non-GAAP EPS estimate moves from $18.52 to $18.60.

Assessment: This is the second consecutive quarter in which Vertex has delivered better revenue than we modelled and no better earnings. That is not an accident or a disappointment; it is the deliberate architecture of a transition year, and management has never pretended otherwise. But it means the case for owning the stock has to rest on 2028 and beyond, and it is 2026 and 2027 earnings that the current multiple is being paid on.

2. The switch accelerated while the flagship's decline narrowed

TRIKAFTA/KAFTRIO declined 2.1% year over year, a third consecutive decline but the mildest of them, while growing 6.1% sequentially. ALYFTREK grew 265.8% year over year and 35.2% sequentially, crossing $1B of first-half revenue. Combined, the pair grew 13.4% year over year, against 7.3% in the first quarter. The question we posed at initiation, whether the switch creates growth or relocates it, now has three quarters of evidence pointing at creation.

The mechanism management describes is a funnel with three inlets rather than one: patients new to therapy, patients returning to therapy, and switchers. The switch cohort dominates today, but the two others are what make the arithmetic additive rather than a wash, and they are being fed by label expansion rather than by promotion.

Assessment: Confirmed, and this is the pillar carrying the whole investment case. The nuance worth holding is that a negative-growth TRIKAFTA changes the risk profile of the franchise even while the total grows. Once the switch cohort is exhausted, growth reverts to net new patients plus price plus geography, and management's own first-half figure of 8% is a fair proxy for what that looks like. Investors modelling low-double-digit CF growth into 2028 are extrapolating a conversion event, not a run rate.

3. Non-CF revenue answered April's question, at 75% sequential growth

In April we wrote that the $500M non-CF target needed roughly double the first-quarter run rate and that reiterating it without a plan did not de-risk it. Non-CF revenue went from $71.9M to $126.0M, up 75.2% sequentially and 197.2% year over year, and the target was reaffirmed unchanged. First-half non-CF revenue of $197.9M leaves $302.1M for the second half, about $151.1M a quarter, roughly 20% above the second-quarter level. That is a far easier task than the roughly 100% step-up the same target implied three months ago.

Management declined to say where the balance comes from.

"CASGEVY has been a bigger contributor than JOURNAVX, but I'm not willing to give further color on the balance of the year other than to say we're very confident in getting to that $500 million plus." — Charles Wagner, Chief Operating Officer and Chief Financial Officer

Assessment: The bear point we opened at EMERGING in April moves to CONTAINED. Two consecutive quarters of this trajectory would make $500M look conservative. The residual issue is not whether the number is reached but what it is made of: if the second half leans on CASGEVY's lumpy, high-cost-of-goods revenue and on JOURNAVX channel dynamics, the target is hit and the gross margin guide gets harder at the same time. Those two disclosures are connected and were not connected on the call.

4. Gross-to-net normalisation slipped for the third consecutive quarter

The date on which JOURNAVX's realised price converges with a normal branded oral has now moved three times: "late 2026, early 2027" in February, "by the end of the year" in May, and now the first half of 2027. Each move has been explained coherently, and this quarter's explanation is arguably the most flattering of the three, that prescription growth is outrunning the payer and physician education needed to stop the patient support programme from being triggered.

The access picture management laid out supports that reading. Of approximately 320 million addressable lives, 260 million are covered and 180 million of those have unrestricted coverage. The 80 million with restricted coverage are where the support programme leaks, and the restrictions described are administrative rather than economic: quantity limits and prior authorisation to indication.

Assessment: The explanation is credible and the underlying trajectory is improving, with implied net revenue per prescription up roughly $13 sequentially. But a milestone that has moved three times in three quarters should be modelled at the late end of whatever range management gives, and the pattern matters more than any individual justification. We now assume no material gross-to-net benefit inside 2026, which is one of the reasons our full-year estimate barely moves on a raised revenue guide.

5. Gross margin stepped down to the full-year level, with the harder half ahead

Non-GAAP gross margin fell 153bps sequentially to 85.6%. That is not a miss; it is what management said would happen, and the full-year framing of "just under 86%" has now been reiterated three quarters running. What is new is the arithmetic implication. First-half gross margin was 86.3%. Holding the full-year guide requires the second half to run near 85.5%, below the quarter just reported.

"Our second quarter 2026 gross margin was 85.6%, an expected sequential step-down from Q1 of '26. This step down reflects the impact of product mix as well as manufacturing network investments in various products. ... The impact from product mix and manufacturing network investment costs will be more pronounced in the second half than they were in the first half of 2026." — Charles Wagner, Chief Operating Officer and Chief Financial Officer

Assessment: The structural point is that diversification has a margin cost and it is now showing up in reported numbers rather than in guidance language. CASGEVY carries a materially higher cost of goods than a small-molecule CF pill, so every dollar of the non-CF success in topic 3 dilutes the margin in topic 5. That trade is worth making. It should simply not be modelled as free, and Vertex's historic 87%-plus gross margin should not be carried into out-year models.

6. Operating expense is now a commercial story, not a research story

Non-GAAP R&D grew 1.2% year over year to $888.7M. Non-GAAP SG&A grew 44.7% to $520.2M. Combined non-GAAP operating expense grew 15.4%, comfortably ahead of 12.5% revenue growth, and management explained the composition directly rather than letting the aggregate stand.

"Note that while R&D continues to account for nearly 2/3 of our operating expenses, the modest growth rate reflects that we are in a period where we can redeploy dollars from programs that wind down to fund programs that are new or scaling up. In contrast, much of our commercial spending is to build new businesses and thus is incremental, as reflected in the higher year-over-year growth rates when compared to R&D spending." — Charles Wagner, Chief Operating Officer and Chief Financial Officer

Second-half combined non-GAAP operating expense has to run about $1,513.8M a quarter to reach the top of the reiterated range, roughly 5.8% above the second quarter's $1,430.3M.

Assessment: The redeployment framing is accurate and it is also the reason R&D growth cannot be read as discipline. Flat research spending in a year when four renal programmes, two type 1 diabetes cell therapies and three next-generation CF correctors are all advancing means something is being wound down to pay for it, and the wind-downs are not itemised. Meanwhile the incremental commercial spend is real, permanent and precedes the revenue it supports by four to six quarters, with povetacicept's field force fully hired against a product that cannot be sold until December at the earliest.

7. The tax rate printed above its own full-year guide

The non-GAAP effective tax rate was 21.1% in the quarter against a full-year guided range of 19.5% to 20.5% that was left unchanged. Management attributed the overage to "some one-time expenses" and pointed to the year-to-date figure of 20.4% as being inside the range, which it is, at the very top.

Assessment: Arithmetically the guide still holds, but only if the second half runs at or below 20.5%, which requires the one-time items not to recur and gives no cushion. This is a small line that does real damage: relative to the prior-year quarter's 19.4%, the higher rate cost roughly 170bps of net income growth, which on a quarter that grew non-GAAP net income 3.2% is not a rounding error. We model the full year at the high end.

8. Crinetics: a fifth pillar bought with the balance sheet, accretive in 2029

Vertex agreed in July to acquire Crinetics Pharmaceuticals for $85.00 per share in cash, approximately $10.0B of equity value and approximately $8.8B net of estimated cash acquired, with closing expected in the third quarter. The strategic case is straightforward and fits the company's model: two lead assets in rare endocrine disease, PALSONIFY and atumelnant, sold to a concentrated group of specialist endocrinologists, which is the same specialty commercial shape as CF and nephrology.

"We believe the 2 lead assets, PALSONIFY and Atumelnant, together represent a peak sales opportunity of about $5 billion." — Reshma Kewalramani, Chief Executive Officer and President

The financial terms are where the analysis has to sit.

"As a reminder, we expect to fund the transaction through a combination of cash on hand and proceeds from a $4.5 billion term loan, and we expect the transaction to become accretive to non-GAAP operating income in 2029." — Charles Wagner, Chief Operating Officer and Chief Financial Officer

Vertex ended the quarter with $13.6B of cash and marketable securities, up from $12.3B at the end of 2025. Applying the disclosed structure to that balance sheet, roughly $4.3B of cash goes out alongside the $4.5B drawn, which would leave cash and investments near $9.3B against $4.5B of term debt, or a net cash position of roughly $4.8B against $13.6B today. Full-year guidance excludes the transaction entirely; management expects the 2026 impact to be "relatively modest" and will re-guide around closing.

Assessment: This changes the third pillar of our thesis rather than confirming it. The balance sheet was never valuable as a number, it was valuable as optionality, and optionality has now been converted into a single concentrated asset with a three-year wait for operating-income accretion. That may prove an excellent use of it. But an investor buying Vertex today is underwriting five franchises of which two generate meaningful revenue, and is doing so with materially less financial flexibility behind them than three months ago. The most striking feature of the call is that a transaction of this size drew not one analyst question, which suggests the Street has already filed it under strategy rather than valuation.

9. Povetacicept has a date, and the incumbent has eGFR data

The FDA accepted the BLA for accelerated approval in IgA nephropathy with a PDUFA target action date of November 30, 2026. That converts our fourth-franchise pillar from an undated filing into a dated, near-term catalyst, and it is the single most valuable thing in the release. On the same day, the already-approved competitor presented kidney-function data, and Q&A pushed management to react to it live. Management had seen only the headline.

"I did just see the eGFR data, but I've just seen the top-line number. And as you say, it shows a stabilization right around 0. That is what we should expect given the proteinuria reduction. So that seems very much in line." — Reshma Kewalramani, Chief Executive Officer and President

Vertex cannot show its own kidney-function data by regulatory design, so its differentiation argument rests on the biomarkers it can show: a 52% change from baseline in proteinuria, plus reductions above 70% in both hematuria and Gd-IgA1, delivered by a once-monthly 0.46ml auto-injector at home.

Assessment: Management's read is that the competitor's kidney-function stabilisation validates the mechanism class rather than differentiating the first mover, and on the science that is the correct reading. The commercial risk is unchanged by it: a product approved since November 2025 will have roughly a year of formulary position and prescriber habit before Vertex can sell anything. We keep this risk at CONTAINED because the data asymmetry is temporary and the biomarker package is genuinely stronger, but the pillar stops being theoretical on November 30 and the launch curve through the first half of 2027 is the real test.

10. Zimislecel timelines deferred for a third consecutive quarter

The type 1 diabetes programme produced one clear advance and one repeated deferral. The advance is that the FDA cleared the IND for VX-017, the universal-donor cell therapy, which management frames as roughly doubling the addressable population from about 60,000 to about 120,000 patients. The deferral is the timeline for zimislecel itself, promised "in the coming months" in February, again in May, and now once more.

"A silver lining to the pause we took in the zimislecel Type A program is that the Type O program time differential versus zimislecel has shortened. Type O is making rapid progress. And thus, we are considering options to further streamline our regulatory strategy and commercialization approach. We expect to provide updated T1D plans, including time lines later this year." — Reshma Kewalramani, Chief Executive Officer and President

Assessment: The honest reading is that the deferral is now explained by something other than the manufacturing pause: Vertex is weighing whether to lead with the universal-donor product instead, which would be a strategy change rather than a delay. That is a defensible reason to withhold a timeline and arguably a better outcome than the original plan. But three consecutive quarters of the same non-answer on the same programme means the market should carry zero value for type 1 diabetes until a date exists, which is how we model it.

11. The bar Vertex has set for its own next-generation cystic fibrosis programmes

The most consequential piece of research strategy on the call was not a data point but a gate. Management stated plainly that ALYFTREK's efficacy has raised the hurdle so high that most successor molecules will not clear it, and committed to killing programmes at Phase 1 rather than advancing them on hope.

"Given the improvements in sweat chloride, ppFEV1, pulmonary exacerbations, hospitalizations, lung transplant and survival that we have seen in patients in clinical trials and/or the real world, we recognize that the unmet need is far lower today and the bar for any medicine to beat ALYFTREK is very, very high. Thus, as we develop our next-gen 3.0 and Beyond programs, we will evaluate multiple regimens in Phase I in cohorts of patients with CF. However, we will only advance assets into Phase II in Beyond that show promise to beat ALYFTREK." — Reshma Kewalramani, Chief Executive Officer and President

Three next-generation correctors are in flight: VX-828 has completed dosing with data due in the second half, while VX-581 and VX-272 are in healthy-volunteer studies.

Assessment: This is the right capital-allocation discipline and it is also an admission with a sharp edge. If the bar to beat ALYFTREK is genuinely very high, then Vertex's own CF research spending has a low expected value, and the franchise's future is a defensive annuity extended by label expansion rather than by innovation. That reframes the CF pillar from a compounding growth engine into a very long, very high-margin tail, which is a perfectly good asset and a different one from what a 25.7x multiple typically implies.

12. Capital returns shrank the share count while the balance sheet was being committed elsewhere

Vertex deployed approximately $455M to repurchase roughly one million shares in the quarter, taking diluted shares to 255.2M from 258.9M a year earlier, a 1.4% reduction. Common shares outstanding fell to 253.3M from 254.0M at the end of 2025. That buyback contributed roughly 1.4 points of the 4.7% non-GAAP EPS growth.

Assessment: A 1.4% net reduction is modest, and in a quarter where the company also committed $8.8B to an acquisition it is worth noting the implied ordering: buybacks continue at a pace that offsets dilution rather than compounds returns, and the strategic capital goes to business development. That is a defensible ordering for a company at this stage. It does mean that the share count is a support for reported EPS growth rather than a driver of it, and that support gets harder to maintain once term debt is being serviced.

Guidance & Outlook

The framing management used is that first-half performance and business momentum earned the raise, which is true. The more useful framing for a model is what the guide requires from here. Applying the midpoint against a first half of $6,320.8M leaves $6,829.2M for the second half. That is 8.0% above the first half sequentially and roughly 9.0% above the year-ago second half, against 10.2% year-over-year growth delivered in the first half. The raised guide therefore embeds a modest deceleration, which management pre-justified by pointing out that prior-year U.S. price increases and foreign exchange, worth about 170bps of growth in the quarter just reported, both fade.

Implied second-half ramp: revenue of about $3,415M a quarter against $3,333.9M just delivered, a 2.4% sequential step. Combined non-GAAP operating expense of about $1,513.8M a quarter to reach the top of the reiterated range, a 5.8% step from Q2. Gross margin near 85.5%, below the 85.6% just printed. Non-CF revenue of about $151.1M a quarter, roughly 20% above the second-quarter level. Every one of those four is achievable; three of the four move against earnings.

Street at: published consensus for the quarter sat at $3,230.6M of revenue and $4.72-$4.75 of non-GAAP EPS, so the beat was on the top line only. Pre-print Street framing looked for roughly 5% earnings growth on close to 9% revenue growth for the quarter, and the guide as raised is consistent with that shape rather than a departure from it. The raise is a revenue raise the Street can put in a model; it is not an earnings raise, and the absence of any upward revision to the expense or tax guidance is why.

Guidance style: Vertex guides conservatively on revenue and precisely on costs, and the pattern held. This is the second consecutive quarter in which revenue exceeded the internal frame while every cost line was reiterated at or steered toward its unfavourable end. The company has now also declined for two consecutive quarters to give a next-quarter revenue frame, a practice it maintained through February. Whatever the reason, it removes the near-term checkpoint that made the annual guide auditable in-quarter.

One structural note on the guide's completeness. It excludes the largest acquisition in the company's history, which is expected to close inside the guidance period. Management characterised the 2026 revenue and operating expense impact as "relatively modest" given the timing and committed to re-guiding at closing. That is reasonable, and it also means the full-year numbers being anchored on today are not the full-year numbers the company will report.

Analyst Q&A Highlights

Twelve analysts from twelve firms, and the distribution is itself informative: the clear majority of the questioning went to pipeline science, four exchanges touched the pain launch, exactly one addressed the path to the non-CF revenue target, and not a single question was asked about the $8.8B acquisition announced four weeks earlier.

The path to the $500M non-CF target, and the split management would not give

The only question of the call directed at the commercial guidance asked how the remaining non-CF revenue splits between the two products. The answer confirmed the aggregate and declined the composition, which is the same posture taken in April on the same question.

Q: "so you've maintained the expectation for at least $500 million of non-CF revenue this year, while CASGEVY and JOURNAVX delivered roughly $125 million this quarter. So as you think about the path to this target, should we expect that the majority of the upside comes from accelerating patient starts with CASGEVY, continued growth with JOURNAVX or kind of a relatively balanced contribution from both franchises."
— Evan Seigerman, BMO Capital Markets

A: "As you pointed out, so far in the first half of the year, CASGEVY and JOURNAVX combined delivered about $200 million in revenue. So we're well on our way to achieving our target of $500 million-plus in that first half. CASGEVY has been a bigger contributor than JOURNAVX, but I'm not willing to give further color on the balance of the year other than to say we're very confident in getting to that $500 million plus."
— Charles Wagner, Chief Operating Officer and Chief Financial Officer

Assessment: The confidence is now backed by arithmetic rather than assertion, which was not true three months ago, and the refusal to split is defensible given CASGEVY's infusion timing genuinely is unpredictable. The reason the composition matters anyway is margin: the two products carry very different costs of goods, so the same $500M produces different gross profit depending on the mix, and the gross-margin guide is the tightest guide the company has. Declining to answer keeps that link unquantifiable.

Where the pain launch is actually constrained

A recurring line of questioning sought the binding constraint on the pain launch now that prescriptions are compounding. The answer located it in administrative friction at the point of prescribing rather than in formulary access or price, which is a meaningfully different problem from the one the revenue line implies.

Q: "And then on the pain front, it was really nice to see the progress here. Maybe help us understand where the bottlenecks lie now or what needs to be worked on with regard to formulary as well as the payer dynamics as you look at co-pay, et cetera."
— Salveen Richter, Goldman Sachs

A: "In terms of the payer side and access, we're very pleased with the coverage that we've secured to date, 200 -- 260 million lives, and that's ahead of those 2 Medicare Part D plans coming in. And I would say we have obviously more work to do to secure the final elements of access for JOURNAVX. And we also have to make sure that those patients whose physicians might have, say, a quantity limit are able to navigate that in order to ensure the patient can secure access."
— Duncan J. McKechnie, Chief Commercial Officer

Assessment: This is the clearest articulation yet of why gross-to-net has kept slipping, and it reframes the problem usefully. The gap is not 60 million uncovered lives, it is the 80 million who have coverage encumbered by quantity limits and prior authorisation, where a prescriber facing a time-sensitive acute pain decision reaches for the support programme instead of fighting the paperwork. That is fixable through education, which is slow and cheap, rather than through contracting, which is fast and expensive. It also explains why the fix keeps taking longer than forecast.

How many days of therapy a prescription actually covers

One exchange went after the volume-per-script variable that sits underneath the revenue line, on the theory that longer prescriptions would be the obvious lever once access is solved. Management closed the lever off.

Q: "But how should we think about the prescribing behavior in terms of how many days of therapy physicians are writing? Has it changed at all in last few quarters or so because it does seem like you have good access, you have good prescription, but probably -- this is probably a missing piece, which could improve here."
— Mohit Bansal, Wells Fargo

A: "To answer your question specifically, as I think we've communicated before, in hospitals, the prescription duration is around about 5 days or so. In retail, it's around about 12, 14 days. So on average, you net out at around about 10 or 11 days or so for each JOURNAVX prescription. And candidly, that dynamic has not changed since the launch because it's really driven by the dynamics of the institution that the patient is in rather than anything else."
— Duncan J. McKechnie, Chief Commercial Officer

Assessment: A straight and useful answer that removes an assumption from a lot of models. Days per prescription is structurally fixed by care setting and will not expand, so JOURNAVX revenue is prescription count multiplied by realised price and nothing else. Given that prescriptions are compounding roughly 45% sequentially and price is the variable that management admits is impaired until 2027, the model is unusually legible: this franchise's revenue inflection is a gross-to-net event on a fixed date, not a demand event.

Reacting to a competitor's kidney-function data live on the call

The most awkward moment of the call arrived when questioning turned to kidney-function results the approved incumbent had released hours earlier, showing stabilisation near baseline. Management had seen only the top line and chose to argue that the result validates the mechanism rather than the competitor.

Q: "I guess the IgAN competitor data to your eGFR data is hot off the press, and it's out there on the tape, and you can see that the approved product has essentially a stabilization of eGFR, if not slightly above the baseline. So to what extent Reshma, given that you have an approval coming up soon, should we think about comparing the 2, either from a launch perspective or perhaps given the strong numbers that they're putting up, it speaks to the significant market opportunity and you can get equivalent share?"
— Michael Yee, UBS

A: "With regard to what it means for the povetacicept IgAN program, I would say all the more reason if anybody needed a little bit more conviction, you can certainly look at these data that were presented today, look at the proteinuria reduction, look at the GFR and reconfirm for yourself that significant reductions in proteinuria should and have resulted in GFR stabilization."
— Reshma Kewalramani, Chief Executive Officer and President

Assessment: Scientifically this is the right answer and it was delivered without hedging, which is a genuine display of conviction on unfamiliar data. Commercially it dodges the question that was asked, which was about share. An incumbent that can put a kidney-function curve in front of a nephrologist has a sales aid Vertex is barred from matching until its own confirmatory data mature. Management's answer converts a competitive disadvantage into evidence for its own mechanism, which is intellectually fair and does nothing for the launch.

Whether kidney function can separate the class at all

A related line of questioning asked the deeper version of the same problem: if every effective agent in this class stabilises kidney function, what is left to differentiate on, and when would it show up? The answer relocated differentiation to an endpoint years beyond any current dataset.

Q: "I'm curious if you expect to see material differentiation on eGFR across the new IgAN products like Pove and its competitors? And if so, over what time horizon do you think any differentiation on that endpoint would become apparent?"
— Jessica Fye, JPMorgan

A: "And I do expect that the medicine that has the stronger reductions in proteinuria, the medicine that gets more patients to less than 0.5 or 0.3, better improvements in hematuria and Gd-IgA1 are more likely to have an improved profile when it comes to that ultimate endpoint. Proteinuria, 1-year GFR, 2-year GFR, these are all endpoints on the way to the ultimate endpoint. And I think that's where you'll see the real differentiation."
— Reshma Kewalramani, Chief Executive Officer and President

Assessment: This is the most consequential answer of the call for anyone underwriting the renal franchise, and it cuts against the investment case even as it defends the science. Management is saying that the endpoint on which povetacicept genuinely separates, time to dialysis, transplant or death, will not be observable for years. Until then the class competes on biomarkers and convenience, where Vertex's package is strong but the first mover's head start is real. The renal pillar is therefore a share-of-voice and execution story through 2027, not a data story, whatever the underlying biology deserves.

What counts as a win at the AMPLITUDE interim

Questioning sought the pre-specified bar for the next major renal readout, and got an unusually concrete answer: the accelerated-approval agreement with the regulator rests on a single named endpoint.

Q: "Wanted to ask about inaxaplin in the AMPLITUDE study? And what kind of data would be necessary in that interim analysis to file for accelerated approval? Basically, like what constitutes the win with this first data look."
— Cory Kasimov, Evercore ISI

A: "We were really pleased and remain very pleased that the agency has provided and we have an agreement with the agency for a potential accelerated approval based on the primary endpoint at the time of the IA, which is 1 year GFR. So that's what our agreement is based on. Obviously, we're also going to look at the proteinuria, but the agreement with the agency for the potential to file for accelerated approval based on the interim analysis is 1-year GFR."
— Reshma Kewalramani, Chief Executive Officer and President

Assessment: Naming the endpoint twice in one answer is the kind of specificity that removes ambiguity from a future readout, and it is welcome. Note the tension with the preceding exchange: kidney function at one year is dismissed as merely "on the way to the ultimate endpoint" when a competitor reports it, and is the agreed basis for accelerated approval when Vertex reports it. Both statements are defensible in their own context. Holding them together is a reminder that the endpoint hierarchy in this field is argued from position as much as from evidence.

The bar a next-generation cystic fibrosis corrector now has to clear

With a competitor's sweat-chloride data approaching, questioning asked how Vertex would judge it, and whether the absolute reduction or the proportion of patients reaching carrier levels is the meaningful measure. The answer set a single threshold and applied it to Vertex's own programmes as well as anyone else's.

Q: "There's a lot of focus on the upcoming data from one of your competitors where we're going to get incremental sweat chloride reductions above TRIKAFTA. We're curious to hear Vertex's opinion on how you're going to interpret that data? Is there a level of sweat chloride reduction that would get your attention or Reshma, as you've suggested in the prepared remarks, is it more about simply the proportion of patients who get to less than 30 millimoles per liter and the exact reduction maybe isn't as meaningful because it can be influenced by things like baseline characteristics?"
— Philip Nadeau, TD Cowen

A: "So with those kind of data, I think that the bar is exceptionally high and rests on getting more patients to less than 30 millimoles. That is the mark and that's the mark that we or anyone else has to hit in order to have a competitive medicine. And of course, it goes without saying it has to be safe, it has to be well tolerated. It has to have good DDIs, it has to be once daily."
— Reshma Kewalramani, Chief Executive Officer and President

Assessment: A well-constructed defensive position, because the threshold Vertex names is one its own product already clears for two-thirds of patients, and any challenger has to clear it while also matching once-daily dosing and drug-drug-interaction profile. The cost of holding that position is the admission embedded in it. If the bar is this high, the CF franchise's forward value comes from label expansion into younger patients and new geographies rather than from a better molecule, which caps the upside on the largest pillar in the company.

Sequencing the two type 1 diabetes cell therapies

Questioning probed whether aligning the filing of the universal-donor programme with the lead programme would push the lead launch out. The answer revealed that the sequencing itself is under review, which is a larger change than the question anticipated.

Q: "And then secondarily, just on zimi. Just wondering if you could talk about the potential impact to launch timing if you do end up syncing the filing with VX-017."
— Brian Abrahams, RBC Capital Markets

A: "And now what we're trying to do is see if we can get the type O program to go even faster and bring that program out either first or very close behind. That's what we're working on in terms of both the regulatory approach and the commercial approach. I don't have a time line for you today, but we should be able to tell you our exact plans with time lines in the back half of this year."
— Reshma Kewalramani, Chief Executive Officer and President

Assessment: The substance is better than the headline. A universal-donor product serving roughly 120,000 patients rather than 60,000, launched first, is a materially larger asset than the original plan, and delaying a timeline to get that sequencing right is good management. The problem is disclosure discipline rather than strategy: this is the third consecutive quarter the same timeline has been promised for the following quarter, and a programme that has been "coming months" away since February should carry no value in a model until a date exists.

What They're NOT Saying

1. The CASGEVY infusion count, for a second consecutive quarter. Withdrawn in April, still absent. Its replacements are floors, not figures: "There were more CASGEVY infusions in the first half of 2026 than in all of 2025", and a third straight quarter of "more than 100 patient initiations". The second construction has now been used three quarters running, which means it has conveyed no information about the trend for nine months. In a quarter where revenue rose 78% sequentially, restoring the metric would have been costless. That it was not restored suggests the intention is to retire it permanently rather than to withhold it during a weak stretch.
2. Any frame for third-quarter revenue. Vertex gave a next-quarter revenue frame in February, gave none in April, and gave none again here. Two consecutive omissions after a period of providing it is a change in practice, not an oversight, and it removes the only in-year checkpoint against which the annual guide could be audited before the year ends.
3. The composition of the remaining $302M of non-CF revenue. Management confirmed CASGEVY has been the larger contributor and explicitly declined to go further. Because the two products carry very different costs of goods, the mix determines whether the gross margin guide gets easier or harder, and that link went unaddressed.
4. What is being wound down inside a flat R&D line. Non-GAAP R&D grew 1.2% in a year that added a Phase 3 in membranous nephropathy, a Phase 2 in myasthenia gravis, a new type 1 diabetes IND and three next-generation CF correctors. Management attributes this to a period in which it can "redeploy dollars from programs that wind down to fund programs that are new or scaling up". The programmes winding down were not named.
5. A restated numeric bar for the AMPLIFIED readout. In April the company pre-committed to a 20% to 40% proteinuria improvement as the threshold for the expanded APOL1 population. Asked about expectations for the same study this quarter, the answer was framed qualitatively, around whether benefit can be derived at low baseline proteinuria, with no numeric bar restated. Softening a pre-committed threshold ahead of the readout is a pattern worth noting.
6. The zimislecel timeline, for a third consecutive quarter. Promised "in the coming months" in February, again in May, and now "later this year." The new explanation, that the universal-donor programme may go first, is more informative than previous ones and still contains no date.
7. Anything about Crinetics economics beyond the deal terms. No revenue contribution estimate, no purchase accounting outline, no interest expense figure for the $4.5B term loan, no view on what leverage does to the buyback. The only forward number offered is that non-GAAP operating income accretion arrives in 2029. For the largest transaction in company history, closing inside the guidance period, that is a thin disclosure, and no analyst pressed it.
8. Where the "one-time expenses" in the tax rate came from. The non-GAAP rate printed above the top of its own full-year range and the overage was attributed to unspecified one-time expenses. Whether they recur determines whether the full-year tax guide holds, and they were not sized.
9. Any update on tariffs. The press release repeats that guidance "continues to include an immaterial cost impact from tariffs in 2026 based on currently known tariff rates and regulations." That is the third consecutive quarter the word immaterial has appeared without a number attached to it.

Market Reaction

• Pre-print setup: VRTX closed at $470.72 on August 3, entering the print up 3.8% year to date against the S&P 500's 11.0%, up 1.9% over the trailing twelve months, and down 10.9% over the trailing thirty days from $528.04 on July 2. The 52-week closing range into the print was $366.54 to $529.59. The stock came into the quarter having given back a meaningful part of a mid-year run, so positioning was not stretched.
• Reaction session: the stock opened at $471.29 on August 4, a 0.1% gap, traded a $465.51 to $488.04 range spanning -1.1% to +3.7%, and closed at $478.71, up 1.7% or $7.99.
• Volume: 2.0M shares against a 1.8M thirty-day average, 1.1 times normal. For a quarter carrying a revenue beat, a guidance raise and a first look at post-deal financials, that is a strikingly ordinary turnover.
• Relative: the S&P 500 rose 1.8% the same session, so VRTX marginally underperformed the tape on the day of its own earnings beat.

The reaction is the most eloquent commentary on the quarter. A 3.2% revenue beat and a raised full-year guide moved the stock 1.7%, in line with a market that rose 1.8% for unrelated reasons, on 1.1 times normal volume. The market read the print exactly as the income statement reads: the revenue line improved and the earnings line did not, so the value of the enterprise barely changed.

The intraday path is more informative than the close. The stock reached $488.04 at its high, up 3.7%, and gave back roughly two-thirds of that by the bell. That shape is consistent with an initial reaction to the revenue headline and the guidance raise, followed by a fade as the expense steer, the gross margin trajectory and the tax rate were absorbed. Nothing in the after-hours or day-of coverage suggests a specific negative catalyst; the fade looks like arithmetic catching up with the headline.

The wider frame matters more for the rating. Since our initiation on May 5, VRTX has returned 12.8% against 6.6% for the S&P 500, roughly 620bps of outperformance in three months. That is a Hold rating that has been wrong on price, and it should be said plainly rather than buried. What has not changed over the same three months is the earnings power: our full-year estimate moved from $18.52 to $18.60. The entire relative return is multiple expansion, from 22.9 times our estimate to 25.7 times.

Street Perspective

Debate: Does the raised guide represent momentum or the absence of it?

Bull view: The bull case being made on the Street is that raising a full-year revenue guide only two quarters in, on a company with Vertex's history of conservatism, signals real confidence, and that the non-CF trajectory of 75% sequential growth means the $500M target is now a floor rather than a stretch. On this reading the guide is deliberately beatable and the second half is set up to clear it.

Bear view: The bear camp contends that a $125M midpoint raise on a $13B base is a rounding error dressed as a signal, that it merely passes through a first-half beat without adding anything to the second half, and that reiterating every single cost line while raising revenue tells you management does not believe the incremental revenue reaches the bottom line. The implied second-half growth rate is below what the first half delivered.

Our take: The bears have the better of this. The raise is real but it is a pass-through, and the tell is that management raised revenue and simultaneously steered operating expense to the high end of its range in the same breath. A company expecting genuine second-half upside does not do both. The 8.0% sequential revenue step implied for the second half against 10.2% first-half year-over-year growth is a deceleration management has already pre-explained.

Debate: Is JOURNAVX a $50M-a-quarter product or a $90M-a-quarter product in disguise?

Bull view: A growing view on the Street is that the reported revenue systematically understates the franchise, because roughly 535,000 prescriptions realising about $93 each against a normalised branded-oral realisation closer to $108 means the reported line is carrying a self-inflicted discount. On this argument, when gross-to-net normalises, revenue steps up without any change in demand, and prescriptions compounding 45% sequentially in the meantime is the only number that matters.

Bear view: Skeptics argue that a gross-to-net gap that has been perpetually one or two quarters from closing across three consecutive calls is not a timing issue but a structural feature of selling a branded non-opioid into an acute setting where prescribers will not fight a prior authorisation, and that the support programme is therefore a permanent cost of doing business rather than a bridge. They also note that this quarter's revenue growth flattered the trend through channel build after a first-quarter drawdown.

Our take: Both sides are partly right and the split is cleaner than either allows. The prescription franchise is real and the demand signal is unambiguous, so the bulls are right that reported revenue understates it today. But the bears are right about the pattern: three consecutive slips on the same milestone means the correct modelling assumption is the late end of any range management offers, and we now carry no material gross-to-net benefit inside 2026. The useful synthesis is that JOURNAVX is a genuine multi-year asset whose revenue inflection is a dated pricing event rather than a demand event, which makes it easier to underwrite and harder to get excited about in the next four quarters.

Debate: Was Crinetics a good use of the balance sheet?

Bull view: The optimistic camp argues Vertex is doing exactly what a cash-generative franchise business should do, converting idle balance sheet into a fifth commercial pillar with roughly $5B of peak sales potential, in a specialty endocrine market whose concentrated prescriber base is the same shape Vertex has executed against for a decade. An approved asset in acromegaly de-risks the deal relative to a clinical-stage acquisition, and paying with cheap term debt against $13.6B of investments is low-risk financing.

Bear view: The bear camp contends that $8.8B for accretion in 2029 is a long wait at a moment when the company is already absorbing two commercial build-outs, that it converts the balance sheet from strategic optionality into a single concentrated bet, and that a company whose central problem is earnings growth failing to track revenue growth has just committed to three more years of exactly that.

Our take: The strategic logic is sound and the timing is questionable. Vertex is buying a fifth franchise before the third and fourth have proven they can carry commercial weight, and it is doing so in the same year its own guide converts roughly 10% revenue growth into low-single-digit earnings growth. The thing that concerns us most is not the price but the silence: a transaction of this scale, closing inside the guidance period, drew no analyst question and disclosed no financial detail beyond the accretion year. Neither management nor the Street is treating this as a valuation event yet, and at some point one of them will have to.

Model Update

The build: revenue of $13,150M at 85.9% non-GAAP gross margin gives $11,296M of gross profit; less $5,750M of combined operating expense gives $5,546M of non-GAAP operating income, a 42.2% margin; plus $440M of net interest income and less $15M of other expense gives $5,971M pre-tax; taxed at 20.5% gives $4,747M of non-GAAP net income; over 255.0M diluted shares gives $18.62, which we round to $18.60. Cross-checking against the reported first half of $9.21 implies a second half of about $9.41, roughly 2% sequential earnings growth on roughly 8% more revenue. That second-half arithmetic is the clearest single expression of what this business is currently doing.

Valuation. At the August 4 close of $478.71 on 253.3M shares outstanding, the market capitalisation is $121.3B. Against $13.6B of cash and marketable securities, enterprise value is $107.6B. On our revised estimate the stock trades at 25.7 times forward non-GAAP earnings, against 22.9 times at our initiation three months ago. Pro forma for Crinetics, applying the disclosed $8.8B net cost and $4.5B term loan to the June 30 balance sheet, net cash falls to roughly $4.8B and enterprise value rises toward $116B.

Fair value. We widen the band by one turn to 22 to 26 times, from 21 to 25 times at initiation. The upgrade is earned by two things: povetacicept moving from an undated filing to a November 30 PDUFA date, and non-CF revenue compounding at 75% sequentially rather than declining. On $18.60 that band is $409 to $484, midpoint $446. Against the $478.71 close, the midpoint implies 6.7% downside and the top of the band implies 1.0% upside. There is no dividend.

Thesis Scorecard Post-Earnings

Overall: The thesis is unchanged in shape and better in detail. Two of the three bull pillars strengthened materially, the leading bear point weakened, and the third bull pillar was traded away for a fifth franchise. But the pillar that governs the rating, the decoupling of earnings growth from revenue growth, was confirmed as emphatically as it could be: the best revenue quarter in six produced 4.7% earnings growth, and the acquisition announced alongside it extends the same pattern to 2029. Business quality strengthened; the earnings arithmetic did not.

Action: Hold. We were wrong on price over the past three months and right on the mechanism, which is an uncomfortable combination and the honest description of where this rating stands. The stock returned 12.8% against the market's 6.6% while our earnings estimate moved 0.4%, so the entire gain is re-rating from 22.9 to 25.7 times. At $478.71 the shares sit 6.7% above our fair value midpoint and 1.0% above the top of a band we have just widened. We would add on a povetacicept approval that comes with a credible launch curve, or on any pullback toward the low $430s, which is roughly our midpoint less a normal quarter's volatility. We would not chase it here, and we would not short a company executing this well into a dated catalyst four months away.